Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

STAT NewsView source article

Part of story

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sourcesCancer immunotherapyCancer & OncologyCancer treatment breakthroughsClinical trialsOncolytic virotherapy
CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3
00

Other sources for this story

Endpoints

CG Oncology's bladder cancer treatment beats expectations in Phase 3

Reuters

CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial | Reuters